☆ 4.7 Article

FDA Approval Summary: Decitabine and Cedazuridine Tablets for Myelodysplastic Syndromes

CLINICAL CANCER RESEARCH (2022)

Related references

Note: Only part of the references are listed.
Editorial Material Oncology

Oncology approvals in 2020: a year of firsts in the midst of a pandemic

Laleh Amiri-Kordestani et al.

Summary: In 2020, despite the challenges posed by the COVID-19 pandemic, the US FDA approved a total of 30 new drugs and biologic agents, 45 supplemental drug and biologic applications, and 1 biosimilar application in the field of oncology.

NATURE REVIEWS CLINICAL ONCOLOGY (2021)

Add to Collection
Article Hematology

Oral cedazuridine/decitabine for MDS and CMML: a phase 2 pharmacokinetic/pharmacodynamic randomized crossover study

Guillermo Garcia-Manero et al.

BLOOD (2020)

Add to Collection
Article Oncology

Myelodysplastic syndromes current treatment algorithm 2018

David P. Steensma

BLOOD CANCER JOURNAL (2018)

Add to Collection
Meeting Abstract Hematology

Preclinical Data In Cynomolgus (cyn) Monkeys Of ASTX727, a Novel Oral Hypomethylating Agent (HMA) Composed Of Low-Dose Oral Decitabine Combined With a Novel Cytidine Deaminase Inhibitor (CDAi) E7727

Aram Oganesian et al.

BLOOD (2013)

Add to Collection
Article Hematology

Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia

Bruce D. Cheson et al.

BLOOD (2006)

Add to Collection
Webinars Posters Questions Hubs Funding Journals Papers Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.